Reading GRCE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GRCE free→Reading GRCE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GRCE free→QuarterlyIQ Insights · GRCE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Vice President of Clinical Operations — Carrie D’Andrea: Carrie D'Andrea ceased serving as Vice President of Clinical Operations and will no longer be employed by the Company.
Other Events On April 23, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter for the Company’s New Drug Application for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On February 12, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “file…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 10, 2026, Grace Therapeutics, Inc. (the “Company”) entered into: • an amendment (the “CEO Amendment”) to that certain Letter Agreement by and between the Company and Prashant Kohli, the Company’s Chief Executive Officer, dated August 12, 2024 (as amended on November 12, 2025 by that certain amendment (“Amendment No. 1”), the “CEO Letter…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On November 13, 2025, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “fil…
Other Events. On October 23, 2025, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously issued in a private placement that the Company closed in September 2023. The remaining 1,190,927 common warrants issued in the 2023 private placement have expired as the 60th day after the U.S. Food and Drug Administration’s acceptance for review of t…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On August 12, 2025, Grace Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Sec…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On June 23, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal year ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On February 13, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not…
Unregistered Sales of Equity Securities. The disclosures in
Entry into a Material Definitive Agreement. Private Placement Offering On February 10, 2025, Grace Therapeutics, Inc. (the “Company”), in connection with a private placement offering of the Company’s securities (the “Offering”), entered into with certain institutional and accredited investors (the “Investors”) (i) a securities purchase agreement involving a placement agent (the “Placement Agent Purchase Agreement”), (ii) a securities purchase agreement not involving a placement agent (the “No…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.